A new COVID-19 treatment, Xevudy (sotrovimab), was approved on Thursday by the Medicines and Healthcare products Regulatory Agency (MHRA) for high-risk adults with symptomatic COVID-19 infection, according to the MHRA official website.

Sotrovimab is a single monoclonal antibody developed by GlaxoSmithKline (GSK) and Vir Biotechnology which is claimed to reduce the risk of hospitalization and death by 79 percent.